Key Details
Price
$51.32Annual Revenue
$572.39 MAnnual EPS
-$0.09PE Ratio
270.10Annual ROE
-5.42%Beta
1.34Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Levi & Korsinsky has informed investors that it is starting an investigation into Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for potential breaches of federal securities laws. This comes after the company announced unsatisfactory results from its RewinD-LB Phase 2b clinical trial for the pain medication suzetrigine on December 19, 2024.
Vertex Pharmaceuticals' suzetrigine had disappointing results in Phase II trials, but I believe there is still potential in the non-addictive pain management sector due to the ongoing opioid crisis. The company's strong position in the cystic fibrosis drug market, especially with the recent FDA approval of Alyftrek, supports its revenue and market growth. Additionally, Vertex's diverse pipeline, which includes treatments for diabetic peripheral neuropathy, IgA nephropathy, type 1 diabetes, and gene editing, suggests good prospects for long-term development.
Vertex Pharmaceuticals (VRTX 0.72%) saw a 13% drop on December 19 after sharing disappointing results from a late-stage clinical trial. However, this decline shouldn't make investors lose faith in the stock's long-term potential; instead, it presents a chance to buy at a lower price for those ready to hold it for a few years.
Vertex (VERX) has the potential to deliver impressive returns due to its strong growth characteristics.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that Dr. Reshma Kewalramani, the CEO and President, will speak at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT. You can watch a live stream of her presentation on the Vertex website in the "Investors" section under "News and Events." A recorded version of the webcast will also be available later.
The FDA's approval is based on late-stage research that indicates VRTX's Alyftrek provides greater benefits to patients than the popular drug Trikafta.
Last week, Vertex Pharmaceuticals Inc (VRTX) revealed that the Phase 2 trial of suzetrigine for treating painful lumbosacral radiculopathy (LSR) achieved its main goal.
Vertex Pharmaceuticals (VRTX 0.16%) was set to be one of the successful biotech companies this year, with its stock rising 27% from January to a high in November. As the top company in cystic fibrosis (CF) treatments, it has a strong history of increasing earnings. Recently, Vertex has also made important strides in expanding into other lucrative treatment markets.
On Friday, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its new treatment for a rare and progressive genetic disease. This approval strengthens the company's leading position in the cystic fibrosis market.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the U.S. Food and Drug Administration (FDA) has approved the broader use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for treating cystic fibrosis (CF) in individuals aged 2 and older. This approval applies to those with at least one F508del mutation in the CFTR gene or a mutation that responds to TRIKAFTA based on clinical or laboratory evidence.
FAQ
- What is the primary business of Vertex?
- What is the ticker symbol for Vertex?
- Does Vertex pay dividends?
- What sector is Vertex in?
- What industry is Vertex in?
- What country is Vertex based in?
- When did Vertex go public?
- Is Vertex in the S&P 500?
- Is Vertex in the NASDAQ 100?
- Is Vertex in the Dow Jones?
- When was Vertex's last earnings report?
- When does Vertex report earnings?
- Should I buy Vertex stock now?